April 7 Review

Today’s A-share market rebound was broad-based, with over 100 individual stocks hitting their daily trading limit. Short-term funds are clustering around targets with high “recognizability,” and market momentum and themes have been truly lively. Fal T-shaped limit-up under the Xin Duo Duo concept—T字涨停—hit limit again; Guo Sheng reversed back to make a new high; and the Tashan-related Xin Duo Duo concept surged once more. The innovative drug sector showed clear divergence: Tianjin Pharma surged on volume, and disagreement shifted to consensus, successfully advancing to a 7th consecutive limit-up; at the close, Wanbang saw 180 million in capital rush in to buy. The current market is focused on two main lines—so let’s look at the detailed analysis. [Taoguba]

I. Strong logic for the Xin Duo Duo concept: weak-market clustering with independent price action

The Xin Duo Duo concept has been strengthening recently, mainly because the market lacks sustained major themes and clear primary main lines. The uncertainty from conflicts has made capital less impacted, leading funds to cluster around targets with more independent price action. Taking Fal as an example: on Friday’s late session, it was pressured by a 30-day “200% anomaly,” but today’s opening call auction directly topped out with a T-shaped limit-up. This propelled other Tashan-related names such as Guo Sheng and Tianyin, as well as Jin Dian, to rise—this is the classic “recognizable clustering” logic in a weak environment. It’s similar to the炒作 of Yida Chewing Gum in March last year: in a background of declining indices, profits in the short term were generated by relying on recognizability.

This profit effect can be reflected in chart patterns, sector style, and even liquidity firms’ seat activity (such as Liu Yizhonglu and Chen Xiaoqün). However, keep in mind the cycle rotates—when things reach the peak, they inevitably decline. For the Tashan-related theme, you can watch Meno’s trading-badge developments: its buy order #4 is Xin Duo Duo, which may indicate opportunities for seat premiums. For Fal and Guo Sheng, treat them from a trend perspective: as long as the pattern doesn’t break down seriously, the risk of dip-buying and continuation should be controllable.

II. The optical fiber main line: Changfei as the base, Fal as the sympathy rebound

The core of the optical fiber sector is Changfei, an institutional trend stock. Fal is its sentiment “sympathy” rebound. After Changfei doubled, Fal began its move—this indicates that Fal’s essence is a short-term funds’ sentiment rebound driven by Changfei’s larger-cycle move. Huiyuan serves as the sector’s sentiment vane: today it hit a one-word limit-up, driving the optical fiber sector higher. If later Huiyuan appears with a high-volume big bearish candle, be alert to the optical fiber sector’s sentiment weakening. Also, after Xin Neng’s reversal and third consecutive limit-up, tomorrow it faces pressure at the 4-limit-up level; if the sector shows divergence, chasing gains should be cautious.

III. Innovative drug main line: Tianjin Pharma becomes the consecutive-limit-up leader; medical is worth expecting to bounce repeatedly

For the innovative drug direction, Tianjin Pharma successfully advanced to a 7th consecutive limit-up. In the early session, although it was affected by divergence and opened high but was instantly sold down after being hit, strong funds quickly took over, turning divergence into consensus. This reflects the leader’s resilience—just like the characteristics of a leader’s走势: board-lot trading today wins meat; tomorrow, follow-up can still make money. As long as Tianjin Pharma doesn’t show an “end signal,” the medical sector still has opportunities for repeated rebounds.

There are two approaches to sector operations: one is to focus on core recognizable targets like Tianjin Pharma and bet on a breakout above the power sector’s 8-limit-up height; if successful, it could drive the short-term consecutive-limit-up sentiment for next month in April. The other is to widen the net across the sector, watching popular trend targets such as Guang’an, Meno, Jimin, and Yibai—primarily relying on support from the 5-day line.

At present, short-term opportunities are concentrated in optical fiber and innovative drugs. Positioning around core recognizable targets or popular trend stocks can capture this wave of “profit-making” effect. If Tianjin Pharma can continue to advance, it will open up the height for short-term consecutive limit-ups, driving the April speculative market—worth key tracking.